RESUMO
Iran National Polio Laboratory [NPL] is a member of the World Health Organization [WHO] Polio Laboratories Network. NPL receives stool specimens from acute flaccid paralysis [AFP] cases from all the provinces throughout Iran for poliovirus detection and identification. Furthermore, the NPL also detects non-polio enteroviruses [NPEVs] in these specimens. Recently, NPEVs have come to be believed to be one of the most important causes of AFP following wild poliovirus. This paper reports the prevalence of different types of NPEVs isolated from the specimens of AFP cases between 1995 and 2000. Stool collection, virus detection and serotype identification were performed according to the WHO standard procedures. A total of 2180 stool specimens from AFP cases were received at the National Polio Laboratory. Coxsackie B viruse and echoviruses 6, 11, 7 and 13 had the highest frequency, identified in 23.7%, 14.4%, 12.7%, 11% and 10.2% of the NPEVs isolated from AFP cases, respectively. Four cases of echovirus 20 were identified, in 2 cases the patiets having died and in one the patient having been afflicted with residual paralysis. There have been no reports of death or residual paralysis [paralysis continuing after 60 days] due to echoviruse 20. Considering the upward trend of AFP cases in Iran, even after wild poliovirus eradication, studies are needed to determine the frequency and type identification of NPEVs and the relationship between NPEVs and residual paralysis in the post-eradication era [2000 onwards].
RESUMO
Objective: To compare the effect of HMG-CoA reductase and ACAT inhibition on the protein and phospholipid contents of perfusate VLDL1 and VLDL2
Design: Experimental study
Animal: Guina pig
Procedure: After anesthesia and abdominal surgery, guinea pig liver was perfused by Krebs-Henslite buffer through completely closed perfusion system.In continue the effect of progesterone, lovastatin and progesterone plus lovastatin on the perfusate VLDL1 and VLDL2 contents was studied.For this reason, VLDL fractions were separarted by cumulative flotation ultracentrifugation ,confirmed by electrone microscopy and in each pool total protein[TOP], total lipid and phospholipid [PL] were measured
Statistical analysis: Percent of 90 minute point mean secretion were compared among different treatment groups by ANOVA.Moreover, slope linear regression between each of treatment group and control was analyzed by t-student test
Results: Progesterone has no significant effect on total lipid,TOP and PL contents of VLDL1 while percent slope changes of linear regression for VLDL2 contents show a significant decrease in lovastatin treatment group [P<0.05]. Lovastatin lowers total lipid [by 20%] in VLDLI and [by 41%] in VLDL2.PL decrease is 20% in VLDL1 and 39% VLDL2.These changes in Progesterone plus lovastatin treatment group are 20% and 40% for total lipid and 21% and 44% for phospholipid
Clinical implications: The effect of HMG-CoA reductase inhibitors on smaller VLDL2 is more than larger VLDL1.These findings are important for using of LDL animal as a model for studying of lipoprotein disorders